Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Trial details
- Registry ID
- NCT05244304
- Phase
- Phase 3
The PDUFA goal date for Tinlarebant (LBS-008) in Stargardt disease type 1 is 12 Feb 2027, as disclosed by Belite Bio, Inc (BLTE).
Drug identity checked against registry records
Also recorded as LBS-008
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304 | BLTE | Phase 3 | Completed | 2025-08-04Actual |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593 | BLTE | Phase 3 | Active not recruiting | 2027-06-30Estimated |
| A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseNCT06388083 | BLTE | Phase 2, Phase 3 | Active not recruiting | 2028-02Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-02-12Day | TinlarebantBelite Bio, Inc · BLTE | Company-disclosed PDUFA goal dateAnnounced review target | Stargardt disease type 1 | Open original sourceRead source excerptU.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027 First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |
| 2027-02-12Day | TinlarebantBelite Bio, Inc · BLTE | Company-disclosed PDUFA goal dateAnnounced review target | Stargardt disease type 1 (STGD1) | Open original sourceRead source excerptNew Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 First seen: 13 Nov 2026 · Evidence last checked: 13 Nov 2026 |